[Invasive aspergillosis in solid organ transplantation].

[Invasive aspergillosis in solid organ transplantation]. Rev Iberoam Micol. 2018 Nov 19;: Authors: Silva JT, Torre-Cisneros J, Aguado JM Abstract Solid organ transplant (SOT) recipients have a high risk for developing invasive fungal infections (IFI). Treatment is difficult due to the interaction between the antifungal and immunosuppressant drugs, as well as the risk of hepatotoxicity and kidney failure associated with voriconazole and amphotericinB, respectively. Isavuconazole is a new antifungal triazole agent with excellent oral bioavailability, predictable and linear pharmacokinetics, good tolerance and low adverse effects. It has been approved for the treatment of invasive aspergillosis and mucormycosis. A review is presented of the reported experience in the use of isavuconazole in SOT. According to the published studies, isavuconazole has a significantly lower risk of interaction with tacrolimus, and is less hepatotoxic than voriconazole. Nevertheless, there is a significant variability between patients, and between each type of SOT. Isavuconazole reduces the side effects associated with the treatment of IFI in SOT. It would be of great interest the implementation of future clinical trials with isavuconazole for the treatment and/or prophylaxis of IFI in these patients. PMID: 30467000 [PubMed - as supplied by publisher]
Source: Revista Iberoamericana de Micologia - Category: Biology Authors: Tags: Rev Iberoam Micol Source Type: research